Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Wiese, Michael D ^a   Schnabl, Matthew ^a   O'Doherty, Catherine ^a   Spargo, Llewellyn D ^b   Sorich, Michael J ^a   Cleland, Leslie G ^b,c   Proudman, Susanna M ^b,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOTRANSFERASE; BREAST CANCER RESISTANCE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; DIHYDROOROTATE DEHYDROGENASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; CYP2C19 PROTEIN, HUMAN; ISOXAZOLE DERIVATIVE;

ABDOMINAL CRAMP; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOATING; BLURRED VISION; COHORT ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; DNA DETERMINATION; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HAIR LOSS; HEMATOLOGIC DISEASE; HOT FLUSH; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENORRHAGIA; MOUTH ULCER; MYALGIA; NAUSEA; PERIPHERAL NEUROPATHY; PHENOTYPE; PNEUMONIA; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SYNCOPE; TASTE DISORDER; VOMITING; WEIGHT REDUCTION; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; GENETICS; MIDDLE AGED; TREATMENT WITHDRAWAL;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CYTOCHROME P-450 CYP2C19; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT;

EID: 84863662901     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3911     Document Type: Article

References (23)

1. Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007, 37:99-111. 10.1016/j.semarthrit.2007.02.001, 17391739.
2. Kalgutkar AS, Nguyen HT, Vaz AD, Doan A, Dalvie DK, McLeod DG, Murray JC. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 2003, 31:1240-1250. 10.1124/dmd.31.10.1240, 12975333.
3. Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, Trdan T, Peterlin Masic L, Mrhar A, Dolzan V. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on A771726 pharmacokinetics in leflunomide treated patients with rheumatoid arthritis. Drug Metab Dispos 2009, 37:2061-2068. 10.1124/dmd.109.027482, 19581389.
4. Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, Nemet K, Heredi-Szabo K, Krajcsi P. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis 2009, 68:1201-1207. 10.1136/ard.2007.086264, 18397960.
5. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002, 1:611-616.
6. Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008, 64:871-876. 10.1007/s00228-008-0498-2, 18496682.
7. Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68:1367-1368. 10.1136/ard.2008.099093, 19605743.
8. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000, 59:841-849. 10.1136/ard.59.11.841, 1753034, 11053058.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA J, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
10. Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010, 363:1704-1714. 10.1056/NEJMoa1008410, 20979470.
11. Ghali WA, Quan H, Brant R, van Melle G, Norris CM, Faris PD, Galbraith PD, Knudtson ML. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001, 286:1494-1497. 10.1001/jama.286.12.1494, 11572743.
12. Seah QM, New LS, Chan EC, Boelsterli UA. Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726. Drug Metab Lett 2008, 2:153-157. 10.2174/187231208785425791, 19356086.
13. Chan EC, New LS. In vitro metabolism of leflunomide by mouse and human liver microsomes. Drug Metab Lett 2007, 1:299-305. 10.2174/187231207783221402, 19356059.
14. Chan EC, New LS, Yap CW, Goh LT. Pharmaceutical metabolite profiling using quadrupole/ion mobility spectrometry/time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2009, 23:384-394. 10.1002/rcm.3887, 19127546.
15. van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, Keuper R, Houtman PM, Brouwers JR. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:569-574. 10.1136/ard.2004.025205, 1755436, 15345501.
16. Chan V, Charles BG, Tett SE. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 2005, 60:257-264. 10.1111/j.1365-2125.2005.02415.x, 1884779, 16120064.
17. Van Roon EN, Jansen TL, Mourad L, Houtman PM, Bruyn GA, Griep EN, Wilffert B, Tobi H, Brouwers JR. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 2004, 57:790-797. 10.1111/j.1365-2125.2004.02075.x, 1884519, 15151525.
18. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999, 47:445-449. 2014233, 10233211.
19. Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur J Clin Pharmacol 2011, 67:129-134. 10.1007/s00228-010-0916-0, 20972558.
20. Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De Keyser F. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001, 44:2255-2262. 10.1002/1529-0131(200110)44:10<2255::AID-ART388>3.0.CO;2-#, 11665966.
21. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon PT, Jabs EW, Nickerson DA, Shendure J, Bamshad MJ. Exome sequencing identifies the cause of a Mendelian disorder. Nat Genet 2010, 42:30-35. 10.1038/ng.499, 2847889, 19915526.
22. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101:1163-1174. 10.1172/JCI992, 508669, 9486988.
23. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999, 162:2095-2102.